HoldoutLabs
Scientific audits for trading strategies
Strategy Fragility Audit
Report 36ee2e7779ea · 2026-09-25 20:43 UTC
holdout-audit 0.4.0 · rubric v1.2

Batch 3: Faber GTAA timing on unseen markets (EEM, VNQ, TLT)

Faber GTAA timing on unseen markets (EEM, VNQ, TLT) on EEM, VNQ, TLT. Claim tested (declared before the run): Timing each asset class with a 10-month SMA gives equity-like returns with bond-like volatility and much smaller drawdowns than buy-and-hold. Benchmark: equal-weight buy-and-hold of the same three ETFs, rebalanced monthly. Part of Indicator Audit Batch 3, 'Strongest published evidence' (6 audits, sealed, Holm across the batch).

Executive summary

Fragility grade
C
15/18 points (83%)

Mixed. Part of the historical edge looks explainable by selection, period or cost effects. The grade measures how fragile the historical evidence is. It is not a forecast and not a recommendation.

Declared objective: reduce drawdown at acceptable cost, declared by the client on 2026-09-25T20:39:29Z (declaration SHA-256 e4fb88120aad0e08…). Declared return-cost tolerance: 1.0% a year.

Benchmark: buy-and-hold of the traded asset. This is the rubric v1.2 default. The drawdown reduction was not robust or exceeded the declared cost, so the grade is at most C.

Max drawdown: strategy vs benchmark
14.5% vs 43.9%
Drawdown reduction (5th pct)
29.4% [3.5%]
Daily CVaR95 reduction
110.4 bps
Return shortfall vs tolerance
3.2% vs 1.0%
Deflated dCVaR (N=8)
1.000
PBO (CSCV, dCVaR)
0.534
Excess Sharpe vs benchmark (95% CI)
-0.22 [-0.65, 0.20]
Excess return a year
-3.2%
Absolute Sharpe
0.54
Deflated Sharpe (N=8)
0.125
PBO (CSCV)
0.917
Holdout excess Sharpe (in → out)
-0.24 → -0.21
Max drawdown
14.5%
Buy-and-hold Sharpe, same period
0.48

The second row is context on the beat-the-benchmark view; it is not graded under the declared objective.

Checks that failed: Primary: return cost within the declared tolerance.

Scorecard

CheckResultValueRule
Selection-adjusted tail-loss reduction (deflated dCVaR)PASSD 1.000 (N = 8)PASS deflated dCVaR >= 0.95; CAUTION >= 0.80; else FAIL (DSR construction on the CVaR reduction)
Probability of backtest overfitting (CSCV, dCVaR)CAUTIONPBO 0.534 (12870 splits)PASS PBO <= 0.20; CAUTION <= 0.50, or PBO > 0.50 with P(OOS dCVaR < 0) <= 0.10; else FAIL (variants ranked by dCVaR)
Multiple-testing adjusted significance of the tail-loss reductionPASSadj. p 0.0001 (BHY)PASS one-sided adjusted p <= 0.05; CAUTION <= 0.10; else FAIL (bootstrap z of dCVaR)
Primary: drawdown and tail-loss reduction vs benchmarkPASSdMDD 29.4% (5th pct 3.5%)PASS 5th-percentile bootstrap dMDD > 0 and dCVaR > 0; CAUTION both point estimates > 0; else FAIL
Primary: return cost within the declared toleranceFAILshortfall 3.2%/yr vs 1.0%PASS 95th-percentile bootstrap return shortfall <= declared tolerance; CAUTION point shortfall <= tolerance; else FAIL
Holdout: tail-loss and drawdown reductionPASSdCVaR 129.1 bps -> 81.7 bpsPASS holdout and in-sample dCVaR > 0, holdout >= 50% of in-sample, and holdout dMDD > 0; CAUTION holdout dCVaR > 0; else FAIL
Stability of the drawdown reductionPASS68% of years shallowerPASS >= 60% of years with a shallower drawdown than the benchmark and dCVaR > 0 in every volatility tercile; CAUTION >= 50%; else FAIL
Transaction-cost headroom (absolute)PASSbreak-even 224.3 bpsPASS break-even cost >= 20 bps per unit traded; CAUTION >= 5 bps; else FAIL (absolute)
Parameter plateau (dCVaR)PASSneighbours 95% of chosenPASS neighbour dCVaR >= 70% of chosen dCVaR; CAUTION >= 40%; else FAIL, or FAIL if chosen dCVaR <= 0

How the grade is set (Holdout Labs Fragility Rubric v1.2, sealed before this report was produced). PASS = 2 points, CAUTION = 1, FAIL = 0; N/A checks are excluded. Share of available points: A ≥ 85%, B ≥ 70%, C ≥ 55%, D ≥ 40%, otherwise F. Hard caps: Objective cap (beat the benchmark): if the strategy does not beat its benchmark (SPA check FAIL, or annualised mean excess return <= 0), the grade is at most C. Objective cap (reduce drawdown): if the drawdown reduction is not robust (drawdown check FAIL) or the declared return-cost tolerance is breached (tolerance check FAIL), the grade is at most C. Objective cap (improve Sharpe): if the Sharpe-ratio improvement is not robust (Sharpe check FAIL), the grade is at most C. Selection cap: if the deflated check FAILS, the grade is at most C. Overfitting cap: if the PBO check FAILS, the grade is at most D. Disclosure cap: if the number of variants tried was not declared and no variant matrix was supplied, the grade is at most B.

Cap applied: Objective cap (reduce drawdown): if the drawdown reduction is not robust (drawdown check FAIL) or the declared return-cost tolerance is breached (tolerance check FAIL), the grade is at most C.

What was audited

Source: Faber, M. T. (2007). A Quantitative Approach to Tactical Asset Allocation. Journal of Wealth Management 9(4), 69-79. Rule: Equal thirds in EEM, VNQ and TLT; each held only while its month-end close is above its 10-month SMA, cash otherwise. Audited variant: months=10|basis=price. Grid: 8 variants.
Sample2005-10-03 to 2026-09-24 (5277 periods, 252 per year)
Variants tried (N)8 · variant matrix of 8 columns supplied
Base-case cost5 bps per unit traded (one way)
Holdout split2018-01-02
Compound annual return, strategy (net)4.5%
Buy-and-hold of the underlying, same periodcompound annual return 6.8%; annualised Sharpe 0.48; max drawdown 43.9%

Results in detail

Growth of 1 (log scale)holdout1220052007200920112013201520172019202120232025StrategyBuy and hold
Growth of 1 on a log scale, net of base-case costs, with buy-and-hold of the underlying in grey. The shaded area is the holdout period.

1. Sharpe ratio and its uncertainty

Rubric checks use the excess series (strategy minus buy-and-hold of the traded asset); the absolute series is shown for reference.

Excess over benchmarkAbsolute
Annualised Sharpe (sqrt-time scaling)-0.2230.536
Annualised Sharpe (Lo 2002 autocorrelation-adjusted)-0.2690.674
Standard error, annualised (non-normal)0.2180.219
Standard error per period: IID-normal / non-normal0.0138 / 0.01370.0138 / 0.0138
Skewness / kurtosis-0.32 / 35.10-0.08 / 7.77
Probabilistic Sharpe ratio vs 00.15320.9928
Minimum track record for 95% confidence∞ years9.5 years
Annualised mean / volatility-3.2% / 14.5%4.8% / 8.9%

2. The variant-count effect (Deflated Sharpe)

Deflated Sharpe ratio against number of variants tried00.20.40.60.811: 0.15312: 0.14325: 0.13058: 0.125810: 0.1231020: 0.1172050: 0.11150100: 0.107100200: 0.103200500: 0.0995001000: 0.0961000variants tried (log scale)
The same backtest, judged as the best of N tries. The dark dot is the declared N = 8; the dashed line is the 0.95 pass mark. Computed on the excess Sharpe over the benchmark. The more variants tried, the higher the bar.
N triedNoise hurdle (annual excess SR)DSR
10.0000.1532
20.0100.1427
50.0230.1299
80.0280.1250
100.0300.1229
200.0360.1172
500.0430.1109
1000.0480.1067
2000.0530.1030
5000.0580.0986
10000.0620.0956

Dispersion of trial Sharpe ratios used: 0.019 (annualised standard deviation), estimated from the variant matrix.

3. Probability of backtest overfitting (CSCV)

Logit of the in-sample winner's out-of-sample rank-2-1012median
PBO0.917
Splits (blocks)12870 (16)
Variants8
P(IS winner trails benchmark out of sample)0.987
Median OOS excess Sharpe of IS winner (annual)-0.27
Degradation slope (OOS on IS)-0.90

Histogram of logit ranks: values left of the dashed line are splits where the in-sample winner finished at or below the out-of-sample median (logit 0).

4. Multiple-testing haircut

t-statistic (excess SR x sqrt(years))-1.02
p-value, single test0.84647
Bonferroni p (8 tests)1.00000
Sidak p1.00000
Holm p1.00000
BHY p1.00000
Haircut excess Sharpe (Bonferroni)-0.000 (100% haircut)
Haircut excess Sharpe (BHY)-0.000

5. Reality Check and SPA

Benchmarkbuy-and-hold of the traded asset
Variants in the test8
Best mean excess return (annualised)-2.75%
White Reality Check p0.947
Hansen SPA p (consistent / lower / upper)1.000 / 1.000 / 1.000
Bootstrapstationary, 1000 draws, mean block 17

6. Holdout degradation

PeriodsAnnualised excess Sharpe
In-sample (before 2018-01-02)3083-0.235
Holdout2194-0.210
Holdout / in-samplen/a
Consistency p-value0.941

7. Period and regime stability

Return minus benchmark return, by calendar year-10%0%10%2005: -0.7%2006: -2.2%2007: 3.0%2008: 12.5%2009: -13.1%2010: -5.9%2011: 2.7%2012: -14.8%2013: -0.2%2014: -11.4%2015: 2.7%2016: -5.7%2017: -6.4%2018: 1.8%2019: -13.3%2020: -6.6%2021: 1.9%2022: 18.7%2023: -11.3%2024: -3.7%2025: -6.0%2026: -3.3%20052007200920112013201520172019202120232025
Strategy compounded return minus benchmark compounded return, by year: ahead in 7 of 22 years (absolute return positive in 14).
Volatility regime (trailing 21-day, lagged)PeriodsAnnualised mean excessAnnualised excess Sharpe
low vol1752-1.8%-0.39
mid vol1752-3.6%-0.55
high vol1752-4.4%-0.18

8. Transaction-cost sensitivity

One-way cost (bps per unit traded)0125102050
Annualised Sharpe0.550.550.540.540.520.500.43
Annualised mean return4.9%4.9%4.8%4.8%4.7%4.5%3.8%

Turnover 2.2 units per year; break-even cost 224.3 bps.

9. Parameter sensitivity

Annualised Sharpe across the parameter gridmonths ↓ / basis →pricetr60.56months=6, basis=price: 0.5620.56months=6, basis=tr: 0.56480.53months=8, basis=price: 0.5300.47months=8, basis=tr: 0.470100.54months=10, basis=price: 0.5360.54months=10, basis=tr: 0.540120.55months=12, basis=price: 0.5460.53months=12, basis=tr: 0.528
Annualised Sharpe by parameter pair. The outlined cell holds the chosen variant.

Chosen variant months=10|basis=price ranks 5 of 8. Grid median Sharpe 0.54, best 0.56; 100% of cells positive; neighbour ratio 1.01.

10. Drawdown distribution

Bootstrap distribution of maximum drawdown20%30%40%realised
Maximum drawdown in 1000 stationary-bootstrap resamples. Realised: 14.5%; median 19.2%; 95th percentile 30.6%. 87% of resamples were worse than the realised drawdown.

11. Declared objective: drawdown reduction at acceptable cost

StrategyBenchmarkReductionBootstrap bound
Maximum drawdown14.5%43.9%29.4%5th pct 3.5%
Daily CVaR95 (bps)135.4245.8110.45th pct 69.7
Return shortfall a year (tolerance 1.0%)3.2%95th pct 7.1%

Deflated dCVaR 1.000 against a best-of-8 hurdle of 7.0 bps; adjusted one-sided p <0.0001. Holdout: dCVaR 129.1 bps before 2018-01-02, 81.7 bps after; holdout drawdown reduction 17.5%. Years with a shallower drawdown than the benchmark: 15 of 22.

What is fragile, and how to test the fix

CAUTION Probability of backtest overfitting (CSCV, dCVaR)

Ranking 8 variants by tail-loss reduction, the in-sample winner ranked in the bottom half out of sample 53.4% of the time and had worse tails than the benchmark out of sample 0.0% of the time.

How to test a fix: Shrink the search and re-run CSCV on the smaller family.

FAIL Primary: return cost within the declared tolerance

The strategy gave up 3.2% a year of arithmetic return against the benchmark (bootstrap 95th percentile 7.1%). The client declared a tolerance of 1.0% a year on 2026-09-25T20:39:29Z.

How to test a fix: The tolerance was fixed in advance and cannot be revised for this audit; a changed rule is a new variant and needs a new declaration.

These are suggestions for further statistical testing, not suggestions to trade. Any change to the rules creates a new variant: count it in N and confirm it on data it was not designed on.

What held up

Methods appendix

Sharpe ratio and its standard error

Per-period mean over standard deviation of the audited return series (risk-free rate taken as zero), annualised by the square root of periods per year. The standard error uses the IID-normal formula of Lo (2002) and the non-normal correction of Mertens (2002), which widens the error for negative skew and fat tails. Lo's autocorrelation-adjusted annualisation is reported alongside. [1], [2]

Probabilistic Sharpe ratio (PSR) and minimum track record

The probability that the true Sharpe ratio exceeds a benchmark (here zero), given the sample length, skewness and kurtosis; and the minimum sample length for 95% confidence. [3]

Deflated Sharpe ratio (DSR)

The PSR measured against the Sharpe ratio one would expect from the best of N skill-less trials, where N is the number of variants tried and the dispersion of trial Sharpe ratios is estimated from the variant matrix (or, without one, set to the null sampling variance 1/T). It corrects for selection and non-normality at once. [4]

Probability of backtest overfitting (PBO) via CSCV

The variant matrix is cut into 16 time blocks; for each of the 12,870 ways of picking half of them as in-sample, the in-sample best variant is ranked out of sample. PBO is the share of splits where it falls to or below the median. It assumes blocks long enough to preserve serial dependence and a variant set that represents the real search. [5]

Multiple-testing haircut

The Sharpe ratio is turned into a t-statistic and p-value, the p-value is adjusted for the number of tests (Bonferroni always; Holm and BHY when every variant's returns are supplied), and the adjusted p-value is mapped back to a haircut Sharpe ratio. [6], [7]

White's Reality Check and Hansen's SPA test

Tests whether the best of all variants beats the benchmark in mean return once the search over variants is accounted for. Uses the stationary bootstrap with mean block length T^(1/3) (at least 5) to keep short-range dependence. SPA studentises and recentres, so poor variants do not dilute the power. [8], [9], [10]

Holdout degradation

In-sample versus holdout Sharpe ratio at a fixed split date (by default the last 30% of the sample). The consistency p-value asks how surprising the holdout Sharpe would be if the in-sample Sharpe were the truth. A holdout only counts if it was not used to design the rule. [11]

Period and regime stability

Returns and Sharpe ratio by calendar year and by tercile of the underlying market's trailing 21-day volatility (lagged one day). Descriptive: the tercile cut points use the full sample. [12]

Parameter-sensitivity surface

Sharpe ratio across the supplied parameter grid. The neighbour ratio compares the chosen cell with its one-step neighbours: a plateau (ratio near 1) is less fragile than an isolated peak. [13]

Transaction-cost sensitivity

Net return = gross return minus turnover times a one-way cost per unit traded, over a grid of costs; the break-even cost is where the mean net return reaches zero. Market impact beyond a flat cost is not modelled. [12]

Drawdown distribution by bootstrap

The maximum drawdown is recomputed on 1,000 stationary-bootstrap resamples of the return series, showing how much deeper (or shallower) the worst loss could plausibly have been with the same return distribution in a different order. [10]

References

  1. Lo, A. W. (2002). The Statistics of Sharpe Ratios. Financial Analysts Journal 58(4), 36-52.
  2. Mertens, E. (2002). Comments on Variance of the IID Estimator in Lo (2002). Working paper, University of Basel.
  3. Bailey, D. H. & Lopez de Prado, M. (2012). The Sharpe Ratio Efficient Frontier. Journal of Risk 15(2), 3-44.
  4. Bailey, D. H. & Lopez de Prado, M. (2014). The Deflated Sharpe Ratio: Correcting for Selection Bias, Backtest Overfitting and Non-Normality. Journal of Portfolio Management 40(5), 94-107.
  5. Bailey, D. H., Borwein, J. M., Lopez de Prado, M. & Zhu, Q. J. (2016). The Probability of Backtest Overfitting. Journal of Computational Finance 20(4), 39-69.
  6. Harvey, C. R. & Liu, Y. (2015). Backtesting. Journal of Portfolio Management 42(1), 13-28.
  7. Harvey, C. R., Liu, Y. & Zhu, H. (2016). ... and the Cross-Section of Expected Returns. Review of Financial Studies 29(1), 5-68.
  8. White, H. (2000). A Reality Check for Data Snooping. Econometrica 68(5), 1097-1126.
  9. Hansen, P. R. (2005). A Test for Superior Predictive Ability. Journal of Business & Economic Statistics 23(4), 365-380.
  10. Politis, D. N. & Romano, J. P. (1994). The Stationary Bootstrap. Journal of the American Statistical Association 89(428), 1303-1313.
  11. Bailey, D. H., Borwein, J. M., Lopez de Prado, M. & Zhu, Q. J. (2014). Pseudo-Mathematics and Financial Charlatanism: The Effects of Backtest Overfitting on Out-of-Sample Performance. Notices of the AMS 61(5), 458-471.
  12. Lopez de Prado, M. (2018). Advances in Financial Machine Learning. Wiley.
  13. Pardo, R. (2008). The Evaluation and Optimization of Trading Strategies, 2nd ed. Wiley.

Data and hash appendix

ItemSHA-256 / value
packageholdout-audit 0.4.0
yahoo_eem.csvef60cb9acb5fcb2801a3e1576cf3d4d74eeae1d2fc6e21efeb08b44e5c1118b8
yahoo_vnq.csv8bc567ef38c35aa59aacd9d40c713590455970c2ac58faff9da458728d8dd3ac
yahoo_tlt.csv9e3ba9c9ac9caa8aa53096e89de089bafb91734efe725d1ef22502764afced84
audited_series_sha25627b4db7e08dc651d624d99f214a1eb13aa980f36da7e8f017239cd106b61bdb4
objective_declaration_sha256e4fb88120aad0e081f71500717f4f73490f446fb92462f7adc9772e8b062a97f
preregistration_sha2562142d17c29db1f2b0080e225cfbcd15ba67582b4122adcc6c78b0aad1325d690
config_sha25636ee2e7779ea3926c514054ab234911b6f840cc5820cf06fbd247342396b3a92
bootstrap seed20260925
rubric version1.2 (docs/RUBRIC-v1.2.md)
declared objectivereduce_drawdown
preregistration seal90ff232e75d552219386a15d1bc0990a86b40a925d2a7dc1405e7be67995e009 (digicert, freetsa; earliest 2026-09-25T20:39:31Z)
objective declaration seal5520ca3004e61782747c0696bec84ee5d2d2e876a86534e31735a433b7905127 (digicert, freetsa; earliest 2026-09-25T20:39:50Z)
rubric document SHA-25681bc60b5bf4520fdfb91c43b37883c30a9a2061903442d1e8a8b05f3d37a71fc
rubric seal record SHA-256142cbfb45314faab8a578b62a17532ac323b0f619f74ab008244163d682db4dd
rubric sealed by digicert (RFC 3161)2026-09-25T20:33:45Z
rubric sealed by freetsa (RFC 3161)2026-09-25T20:33:46Z

Anyone with the same inputs and package version can re-run the audit and must obtain the same audited-series hash and the same statistics.

Important. This report is a statistical analysis of historical data supplied by or selected for the client. It describes how fragile past results are under standard tests; it says nothing reliable about future results. It is not investment advice, not a recommendation to buy, sell or hold any security or other instrument, and not an offer of any service regulated as investment or trading advice. Past performance, simulated or real, does not guarantee future results. No warranty is given that the data, code or conclusions are free of error. Backtested and simulated results are hypothetical and have inherent limitations.